This may be interest to members.
The National Blood Authority is advising of the transition from Australia’s domestic subcutaneous immunoglobulin (SCIg) product EVOGAM to HIZENTRA AU. The new product will continue to be manufactured from Australia’s plasma and is approved by the Therapeutics Goods Administration in accordance with usual high standards of safety and quality.
From 2 August 2023, patients on EVOGAM will begin transitioning to HIZENTRA AU. The timing of when each patient will transition will be determined by their treating team and we anticipate most patients to be transitioned by October 2023.
The handout below gives more information on this: